{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '8.3.3', 'Local Skin Reactions', 'At every study visit (except Screening), the Investigator or designee will evaluate LSRs known to', 'be associated with retinoids (burning/stinging, erythema, erosions, and edema) or other causes', 'regardless of blinded causality assessment within the areas treated with study medication using a', '4-point ordinal scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Note: At Visit 2', '(Baseline), the LSR assessment must be performed prior to the application of study medication.', 'Only LSRs that require medical intervention (eg, prescription medication) or that require', 'withholding application of the study medication will be documented as AEs. Any LSRs that are', 'not listed above will be recorded as AEs. For drug interruption due to LSRs, refer structured drug', 'interruption scheme (drug holiday) described in Section 7.4.', '8.3.4', 'Electrocardiograms', 'Electrocardiogram monitoring will not be performed in this study.', '8.3.5', 'Clinical Safety Laboratory Assessments', 'Urine and blood samples will be collected from each subject for safety laboratory analyses at', 'Visit 1 (Screening) and Visit 6 (EOS).', 'Subjects must be fasting (at least 8 hours) for Visit 1 (Screening) and, if possible, for Visit 6 (EOS);', 'however, if a subject arrives at the clinic for Visit 6 (EOS) without fasting for at least 8 hours,', 'laboratory specimens may be collected as non-fasting, at the discretion of the Investigator, and', 'with the appropriate fasting status documented on the laboratory requisition form.', 'For subjects that will have the Visit 6 (EOS) conducted remotely, urine and blood samples may be', 'collected by a home health care provider supplied by the Sponsor.', 'See Appendix 3 for the list of clinical laboratory tests to be performed and to the Schedule of', 'Activities (Section 1.2) for the timing and frequency.', 'The Investigator must review the laboratory report, document this review, and record any clinically', 'relevant changes occurring during the study in the AE section of the eCRF. The laboratory reports', 'must be filed with the source documents. Clinically significant abnormal laboratory findings are', 'those that are not associated with the underlying disease unless judged by the Investigator to be', \"out of range to a greater degree than expected for the subject's condition.\", 'All laboratory tests with values considered clinically significantly abnormal during participation', 'in the study or within 30 days after the last dose of study medication should be repeated until the', 'values, stabilize, return to normal or Baseline, or are no longer considered clinically significant by', 'the Investigator or Medical Monitor.', 'If such values do not return to normal/Baseline within a period judged reasonable by the', 'Investigator, the etiology should be identified, and the Sponsor should be notified.', '41']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'All protocol-required laboratory assessments, as defined in Appendix 3, must be conducted', 'in accordance with the laboratory manual and the Schedule of Activities (Section 1.2).', 'If laboratory values from non-protocol-specified laboratory assessments performed at the', \"institution's local laboratory require a change in subject management or are considered\", 'clinically significant by the Investigator (eg, SAE, AE, dose interruption), then the results', 'must be recorded in the eCRF.', 'Any new or worsening of clinically significant abnormalities at Visit 6 (EOS) will be recorded as', 'AEs.', '8.4', 'Adverse Events', 'All AEs will be recorded. At each post-Baseline Visit, subjects will also be questioned specifically', 'about the status of any ongoing AEs.', 'The definitions of an AE or SAE can be found in Appendix 4.', 'Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or', \"the subject's legally authorized representative).\", 'The Investigator and any designees are responsible for detecting, documenting, and recording', 'events that meet the definition of an AE or SAE and remain responsible for following up AEs that', 'are serious, considered related to the study medication or study procedures, or that caused the', 'subject to discontinue the study (see Section 7.0). The trial blind may be broken for an individual', 'only if knowledge of the IMP is essential for clinical management of the subject.', '8.4.1', 'Time Period and Frequency for Collecting Adverse Event and Serious Adverse', 'Event Information', 'All AEs and SAEs will be collected from signing the ICF until the Visit 6 (EOS) at the time points', 'specified in the Schedule of Activities (Section 1.2).', 'All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated', 'in Appendix 4. The Investigator will submit any updated SAE data to the Sponsor within 24 hours', 'of it being available.', 'Investigators are not obligated to actively seek AE or SAE information after the conclusion of', 'study participation. However, if the Investigator learns of any SAE, including a death, at any time', 'after a subject has been discharged from the study, and he/she considers the event to be reasonably', 'related to the study medication or study participation, the Investigator must promptly notify the', 'Sponsor.', 'The methods of recording, evaluating, and assessing the causality of AEs and SAEs and the', 'procedures for completing and transmitting SAE reports are provided in Appendix 4.', '42']\n\n###\n\n", "completion": "END"}